Tablet Production White Papers & Case Studies

  1. 5 Steps To Increase Energy-Efficient Mixing
    3/1/2018

    Mixer testing simulation trials are needed to confirm the suitability of a specific mixing strategy. This white paper explores five ways to increase energy efficiency in new and existing mixing processes.

  2. Efficiencies In Powder Dispersion For Manufacturers
    3/1/2018

    Uniformly dispersing powders into a liquid batch in a practical amount of time is a common problem for F&B manufacturers. This white paper explores five tips for dispersing powders more efficiently.

  3. How To Optimize Solid-Liquid Mixing
    3/1/2018

    This paper provides practical information on the efficient use of specialty mixing equipment for the preparation of low, medium and high viscosity solid-liquid mixtures under low and high shear conditions.

  4. Development Of Biopharmaceuticals Requiring Lyophilized Formulations
    1/18/2018

    Development of a drug formulation and lyophilization (freeze drying) process begins with laboratory experiments followed by scale up to larger lyophilizers. 

  5. Revolutionizing Allergy Therapy
    8/11/2017

    ALK-Abelló is a global research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies. Before ALK-Abelló partnered with Catalent, all marketed allergen immunotherapies were delivered by injection, resulting in a limited patient population and reduced patient adherence. Catalent worked with the client to apply Zydis Fast Dissolve Technology to their therapy. The overall result was a marked improvement in patient tolerability, preference and compliance.

  6. The Importance Of Land Width On Pharmaceutical Tablet Design
    6/10/2016

    Tablet land is beneficial to add strength and durability to the punch tip. But, this hand land may be perceived as making it more difficult to coat the tablet.

  7. Improving Suspendibility Of A Water-Insoluble API For Oral Suspension
    4/15/2016

    In this case study, API (X) is a highly insoluble compound with a particle size of approximately 14 microns and targeted as a powder for oral suspension dosage form.

  8. In Vivo Study And The Impact Of The Dissolution Rate On Bioequivalence
    2/5/2016

    Comparative human in-vivo study of an immediate release tablet over-encapsulated by gelatin and hydroxypropyl methyl cellulose capsules – impact of dissolution rate on bioequivalence.

  9. Using QbD For Process Optimization Of A Novel Oral Solid Dosage Form
    11/10/2015

    As stated in the International Conference on Harmonisation Harmonised Tripartite Guidance on Pharmaceutical Development, ICH Q8 (R2), “The aim of pharmaceutical development is to design a quality product and its manufacturing process to consistently deliver the intended performance of the product.”1 Several tools are available as guidance issued by FDA such as “Quality Systems Approach to cGMP Manufacturing”2 that includes ideas such as Quality by Design (QbD) in the development process. This guidance, amongst others, lay the framework for expectations of regulatory reviewers in their examination of client submittal documentation.

  10. Modular Facility Design: A Cost-Effective Option In The Post-Blockbuster Drug Era
    9/1/2015

    The pharmaceutical industry has undergone a sea of change in recent years as manufacturers have adapted to the end of the era of large-volume production of mass-market blockbuster drugs. With firms now focusing in on subpopulations of patients, there is a need for lean, adaptable facilities that can switch quickly between multiple products in multiple formats. Modular facilities can meet this need. While not a panacea, for the right project characteristics, ‘Modularity in Design’ can deliver significant and quantifiable long-term value.